SHR2285, the first selectively oral FXIa inhibitor in China: Safety, tolerability, pharmacokinetics and pharmacodynamics combined with aspirin, clopidogrel or ticagrelor

Purpose: To evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of SHR2285, the first oral coagulation factor XIa (FXIa) inhibitor developed in China in combination with aspirin, clopidogrel or ticagrelor in healthy subjects. Methods: This study was a single-center, randomized,...

Descripción completa

Detalles Bibliográficos
Autores principales: Ma, Tingting, Dong, Yanli, Huang, Lei, Yang, Yuanxun, Geng, Yan, Fei, Fei, Xie, Pinhao, Zhao, Yu, Lin, Hui, Yang, Zeyu, Jin, Yun, Ju, Xitong, Sun, Runbin, Li, Juan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9626527/
https://www.ncbi.nlm.nih.gov/pubmed/36339534
http://dx.doi.org/10.3389/fphar.2022.1027627

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9626527/
https://www.ncbi.nlm.nih.gov/pubmed/36339534
http://dx.doi.org/10.3389/fphar.2022.1027627

Ejemplares similares